Abstract
A simple method is described to study and compare COVID-19 infection dynamics between countries, based on curve fitting to publicly shared data of confirmed COVID-19 infections in them. The method was tested using data from 80 countries from 6 continents. We found that Johnson Cumulative Distribution Functions (CDF) were extremely well fitted to the data (R2>0.99) and that Johnson CDFs were much better fitted to the data at their tails than either the commonly used Normal or Lognormal CDFs. Fitted Johnson CDFs can be used to obtain basic parameters of the infection wave, such as the percentage of the population infected during an infection wave, the days of the start, peak and end of the infection wave, as well as the durations of the infection wave of the wave’s increase and decrease. These parameters can be easily interpreted biologically and used both for describing the infection wave dynamics and in further statistical analysis. The usefulness of the parameters obtained was analysed with respect to the relation between the Gross Domestic Product (GDP) per capita and the population density, and the percentage of the population infected during an infection wave, the starting day and the duration of the infection wave in the 80 countries. We found that all the above parameters were significantly dependent on the GDP per capita, but only the percentage of the population infected was significantly dependent on the population density in these countries. If used with caution, this method has a limited ability to predict the future trajectory and parameters of an ongoing infection wave.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was financed partly by the statutory funds of the Institute of Nature Conservation, Polish Academy of Sciences and partly by the statutory funds of the Faculty of Applied Mathematics, AGH University of Science and Technology.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This is the corrected (by english native speaker) version of the MS, which will be submitted.
Data Availability
The data used in this study was obtained from Our World in Data COVID-19 dataset and are available at https://ourworldindata.org/coronavirus
